Nazim Isma

Medicine & Life Sciences

1. Activated Protein C Resistance 13%
2. Acute Coronary Syndrome 18%
3. Anticoagulants 55%
4. Atrial Fibrillation 37%
5. bivalirudin 27%
6. Chest Pain 18%
7. Cohort Studies 25%
8. Coronary Vessels 15%
9. Dalteparin 28%
10. Elderly 12%
11. Epidemiology 30%
12. Extremities 13%
13. factor V Leiden 59%
14. Fibrinogen 13%
15. First Labor Stage 24%
16. Head 13%
17. Heart Diseases 31%
18. Hemoglobins 17%
19. Hemorrhage 22%
20. Heparin 18%
21. Incidence 14%
22. Ischemia 14%
23. Low Molecular Weight Heparin 26%
24. Mortality 26%
25. Mutation 27%
26. Myocardial Infarction 33%
27. Observational Studies 17%
28. Orthostatic Hypotension 23%
29. Percutaneous Coronary Intervention 41%
30. Population 19%
31. Pulmonary Embolism 16%
32. Recurrence 16%
33. Registries 15%
34. Safety 12%
35. ST Elevation Myocardial Infarction 20%
36. Stroke 19%
37. Sweden 34%
38. Syncope 40%
39. Therapeutics 14%
40. Thromboembolism 21%
41. Thrombophilia 86%
42. Ticagrelor 26%
43. Troponin T 22%
44. Upper Extremity 21%
45. Veins 15%
46. Venous Thromboembolism 100%
47. Venous Thrombosis 53%
48. Vitamin K 24%
49. Von Willebrand antigen 20%
50. von Willebrand Factor 36%